Skip to main content

Tetanus toxoid Disease Interactions

There are 3 disease interactions with tetanus toxoid.

Major

Vaccination (applies to tetanus toxoid) infections

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. (2022) "Product Information. Typhim VI (typhoid vaccine, inactivated)." Apothecon Inc
  2. (2022) "Product Information. Varivax (varicella virus vaccine)." Merck & Co., Inc
  3. (2022) "Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine)." Merck & Co., Inc
  4. (2022) "Product Information. Mumpsvax (mumps virus vaccine)." Merck & Co., Inc
  5. (2022) "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc
  6. (2022) "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc
  7. (2022) "Product Information. Orimune (poliovirus vaccine, live, trivalent)." Lederle Laboratories
  8. (2001) "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur
  9. "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham
  10. "Product Information. Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught Laboratories Inc
  11. (2001) "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc
  12. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. (1997) "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics
  13. "Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories
  14. "Product Information. Havrix (HepA) (hepatitis A adult vaccine)." SmithKline Beecham
  15. (2022) "Product Information. Engerix-B (HepB) (hepatitis B adult vaccine)." Apothecon Inc
  16. (2006) "Product Information. Zostavax (zoster vaccine live)." Merck & Co., Inc
  17. (2006) "Product Information. Gardasil (human papillomavirus vaccine)." Merck & Co., Inc
  18. (2016) "Product Information. Gardasil 9 (human papillomavirus vaccine)." Merck & Co., Inc
View all 18 references
Major

Vaccines (applies to tetanus toxoid) IM injection

Major Potential Hazard, High plausibility. Applicable conditions: Thrombocytopenia, Coagulation Defect, Thrombocytopathy

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. (2001) "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc
  2. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. (1997) "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics
  3. "Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories
  4. "Product Information. Havrix (HepA) (hepatitis A adult vaccine)." SmithKline Beecham
  5. (2022) "Product Information. Engerix-B (HepB) (hepatitis B adult vaccine)." Apothecon Inc
  6. (2005) "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur
  7. (2022) "Product Information. ActHIB (Hib) (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur
  8. (2010) "Product Information. Imogam Rabies-HT (rabies immune globulin, human)." sanofi pasteur
  9. (2015) "Product Information. Hyperrab S/D (rabies immune globulin, human)." Grifols Therapeutics
  10. (2022) "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc
View all 10 references
Moderate

Vaccines (inactivated)/toxoids (applies to tetanus toxoid) immunodeficiency

Moderate Potential Hazard, High plausibility.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

References

  1. (2001) "Product Information. Tetanus Toxoid Adsorbed (tetanus vaccine)." Aventis Pharmaceuticals
  2. (2022) "Product Information. Typhim VI (typhoid vaccine, inactivated)." Apothecon Inc
  3. (2022) "Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine)." Merck & Co., Inc
  4. "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc
  5. "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham
  6. "Product Information. Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught Laboratories Inc
  7. (2001) "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc
  8. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. (1997) "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics
  9. "Product Information. Havrix (HepA) (hepatitis A adult vaccine)." SmithKline Beecham
  10. (2022) "Product Information. Engerix-B (HepB) (hepatitis B adult vaccine)." Apothecon Inc
  11. (2006) "Product Information. Gardasil (human papillomavirus vaccine)." Merck & Co., Inc
  12. (2009) "Product Information. Cervarix (human papillomavirus vaccine)." GlaxoSmithKline
  13. (2022) "Product Information. Prevnar 13 (pneumococcal 13-valent conjugate vaccine)." Apothecon Inc
  14. (2016) "Product Information. Gardasil 9 (human papillomavirus vaccine)." Merck & Co., Inc
View all 14 references

Tetanus toxoid drug interactions

There are 288 drug interactions with tetanus toxoid.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.